Last reviewed · How we verify
Carvedilol+Empagliflozin
Carvedilol+Empagliflozin combines a non-selective beta-blocker with an SGLT2 inhibitor to reduce heart workload and improve cardiac efficiency while promoting glucose excretion.
Carvedilol+Empagliflozin combines a non-selective beta-blocker with an SGLT2 inhibitor to reduce heart workload and improve cardiac efficiency while promoting glucose excretion. Used for Heart failure with reduced ejection fraction, Type 2 diabetes mellitus with cardiovascular disease.
At a glance
| Generic name | Carvedilol+Empagliflozin |
|---|---|
| Also known as | Dilatrend SR+Jardiance |
| Sponsor | Asan Medical Center |
| Drug class | Beta-blocker + SGLT2 inhibitor combination |
| Target | Beta-adrenergic receptors; SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular, Diabetes |
| Phase | Phase 3 |
Mechanism of action
Carvedilol blocks beta-adrenergic receptors to reduce heart rate, blood pressure, and myocardial oxygen demand, providing cardioprotective effects. Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and reduce blood glucose, while also providing cardiovascular and renal protective benefits through hemodynamic and metabolic mechanisms.
Approved indications
- Heart failure with reduced ejection fraction
- Type 2 diabetes mellitus with cardiovascular disease
Common side effects
- Hypotension
- Bradycardia
- Dizziness
- Fatigue
- Genital mycotic infections
- Urinary tract infections
Key clinical trials
- HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy (PHASE2)
- A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis (NA)
- DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis (PHASE4)
- An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
- RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy (NA)
- Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction (PHASE4)
- Pharmacological Reduction of Right Ventricular Enlargement (PHASE3)
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD " (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carvedilol+Empagliflozin CI brief — competitive landscape report
- Carvedilol+Empagliflozin updates RSS · CI watch RSS
- Asan Medical Center portfolio CI